STEMCELL Technologies Announces Acquisition of Propagenix Inc.
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
- STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
- View the full release here: https://www.businesswire.com/news/home/20240119648511/en/
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine. - (Pictured: STEMCELL's headquarters in Vancouver, BC) (Photo: Business Wire)
“The acquisition of Propagenix is an important step in STEMCELL’s growth journey and an achievement for Canada's biotechnology industry,” said Dr. Allen Eaves, President and CEO, STEMCELL. - “We are delighted that the amazing team of scientists at STEMCELL will ensure Propagenix technologies and capabilities for epithelial cell biology are deployed to their fullest to serve the life science research community,” said Dr. Brian Pollok on behalf of Propagenix co-founders.